Altria
MO
$72.19
+2.25%
Altria Group, Inc. is a leading tobacco company in the United States, operating in the Consumer Defensive sector with a core business encompassing cigarettes, smokeless tobacco, and cigars. The company is a dominant market leader, holding the top position in cigarettes and smokeless tobacco domestically, primarily through its flagship Marlboro brand which commands a 40% market share. The current investor narrative revolves around the company's high-yield dividend appeal and its ongoing strategic pivot towards reduced-risk products, such as its acquisition of Njoy Holdings and its stake in Cronos, as it navigates the secular decline in traditional smoking and attempts to build a sustainable future beyond combustible tobacco.…
MO
Altria
$72.19
Related headlines
Investment Opinion: Should I buy MO Today?
Rating: Hold. The core thesis is that Altria is a high-yield, defensive stock suitable for income portfolios, but its severe financial leverage and secular challenges cap its upside potential, making it a hold rather than a compelling buy at current levels.
The stock's forward P/E of 12.0x is reasonable for its sector, and the 7.2% dividend yield is a powerful income stream. Revenue showed a solid 14.5% YoY growth last quarter, and profitability remains high with a trailing net margin of 34.5%. However, the lack of a clear analyst average target price and the limited coverage of only 6 analysts make it difficult to quantify a standard upside catalyst, underscoring the market's cautious stance.
The two biggest risks that could invalidate a Hold thesis are a dividend cut, triggered by a sustained drop in free cash flow below the payout requirement, and an acceleration in cigarette volume decline that outpaces price increases. This Hold would upgrade to a Buy if the forward P/E compressed below 10x, offering a greater margin of safety, or if the company demonstrated clear, accelerating market share gains in its reduced-risk product portfolio. It would downgrade to a Sell if quarterly revenue growth turned negative or if the debt-to-equity ratio deteriorated further. Relative to its own volatile history and the risks it faces, the stock appears fairly valued, not egregiously overvalued or deeply undervalued.
Sign up to view all
MO 12-Month Price Forecast
Altria presents a neutral, income-oriented investment with defined asymmetric risks. The high yield and low valuation provide downside protection, but the catastrophic balance sheet leverage and secular decline of the core business limit long-term capital appreciation potential. The stance is predicated on the company's ability to maintain its dividend, which is currently supported by strong cash flow. This neutral view would upgrade to bullish if evidence emerges that smoke-free products can become a material profit contributor within 3-5 years, or if the company makes substantial progress in debt reduction. It would turn bearish if quarterly free cash flow trends downward for two consecutive quarters or if cigarette shipment volumes show an accelerated decline.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Altria's 12-month outlook, with a consensus price target around $93.85 and implied upside of +30.0% versus the current price.
Average Target
$93.85
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$58 - $94
Analyst target range
Analyst coverage for Altria is limited, with only 6 analysts providing estimates, which is low for a company of its market cap and indicates constrained institutional research interest. The consensus sentiment, inferred from the sparse institutional ratings data, appears mixed, with recent actions including 'Buy' ratings from UBS and Stifel but an 'Underweight' from Barclays and a 'Neutral' from Citigroup. The average target price is not explicitly provided in the data, so the implied upside or downside cannot be calculated from the given inputs. The target price range is also not specified in the provided analyst data. The wide dispersion in analyst actions—from Buy to Underweight—signals high uncertainty and debate regarding the stock's prospects, likely centered on the sustainability of the dividend, the pace of the transition to smoke-free products, and regulatory risks. The limited coverage itself is a notable characteristic, often associated with stocks facing secular challenges, and can contribute to higher volatility and less efficient price discovery compared to more widely followed peers.
Bulls vs Bears: MO Investment Factors
The investment case for Altria is a classic tension between high current income and long-term existential risk. The bull case, supported by a 7.2% dividend yield, dominant market share, and a forward P/E of 12.0x, currently holds stronger evidence for income-seeking investors in the near term. However, the bear case, anchored by a severe debt-to-equity ratio of -7.34 and the secular decline of its core business, presents a formidable long-term challenge. The single most important tension is the race between the company's ability to generate sufficient cash from its legacy business to fund dividends and debt repayment versus the accelerating decline of that very cash cow before its reduced-risk product portfolio can achieve meaningful scale.
Bullish
- High Dividend Yield & Strong Cash Flow: MO offers a compelling dividend yield of 7.2%, supported by robust trailing free cash flow of $9.07 billion. The payout ratio of 100.2% is high but sustainable given the company's consistent cash generation and defensive business model.
- Dominant Market Position & Pricing Power: Altria's Marlboro brand commands a 40% U.S. cigarette market share, underpinning its pricing power and stable revenue base. This dominance is reflected in the company's exceptionally high trailing gross margin of 86.6% and operating margin of 74.8%.
- Attractive Valuation Relative to Earnings: The stock trades at a forward P/E of 12.0x, below the trailing P/E of 13.9x, indicating the market expects modest earnings growth. This valuation is reasonable for a company with a trailing net margin of 34.5% and provides a margin of safety for income-focused investors.
- Strategic Pivot to Reduced-Risk Products: Investments in Njoy (vaping), Cronos (cannabis), and the On nicotine pouch brand represent a credible, albeit nascent, pathway to offset the secular decline in combustible tobacco. Recent quarterly revenue growth of 14.5% YoY suggests some success in this transition.
Bearish
- Severe Balance Sheet Leverage: The company has a dangerously high debt-to-equity ratio of -7.34, stemming from negative shareholder equity. This significant leverage, coupled with a low current ratio of 0.61, presents a material financial risk, especially in a rising interest rate environment.
- Secular Decline in Core Business: Altria's future is fundamentally challenged by the long-term decline in cigarette smoking. The company remains heavily reliant on its Smokeable Products segment, which generated $5.12B of the last quarter's $5.85B revenue, highlighting the slow pace of transition.
- Limited Analyst Coverage & High Uncertainty: Only 6 analysts cover the stock, indicating constrained institutional interest and potentially less efficient price discovery. The wide dispersion in ratings—from 'Buy' to 'Underweight'—signals high uncertainty about the company's strategic pivot and dividend sustainability.
- Earnings Volatility & Margin Compression: Profitability is inconsistent, as seen in the net margin compression from 59.5% in Q4 2024 to 19.1% in Q4 2025. This quarterly volatility, driven by tax impacts and one-time items, complicates earnings forecasting and undermines the stability narrative.
MO Technical Analysis
The stock is in a sustained uptrend, evidenced by a 1-year price change of +19.04% and a 6-month gain of +21.75%. As of the latest close of $70.60, the price is trading at approximately 95% of its 52-week high of $74.56, indicating strong momentum but also positioning the stock near potential technical resistance. This proximity to the high suggests the rally may be mature, requiring a decisive breakout to sustain further gains. Recent momentum shows a short-term pullback, with the stock down -3.01% over the past month, which contrasts with the strong 3-month gain of +6.15%. This divergence signals a potential consolidation or profit-taking phase after the sharp rally from the January lows near $54.72. The stock's beta of 0.519 indicates it is roughly half as volatile as the broader market, which is characteristic of a defensive consumer staple and implies lower relative risk during market downturns. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $74.56 and major support at the 52-week low of $54.70. A breakout above $74.56 would confirm the bullish trend continuation, while a breakdown below the $54.70 support would signal a significant trend reversal and potential re-test of lower levels.
Beta
0.50
0.50x market volatility
Max Drawdown
-19.1%
Largest decline past year
52-Week Range
$55-$75
Price range past year
Annual Return
+21.6%
Cumulative gain past year
| Period | MO Return | S&P 500 |
|---|---|---|
| 1m | +2.9% | -0.0% |
| 3m | +8.5% | +8.7% |
| 6m | +24.5% | +8.0% |
| 1y | +21.6% | +23.1% |
| ytd | +26.0% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MO Fundamental Analysis
Revenue growth is modest but positive, with the most recent quarterly revenue of $5.85 billion representing a year-over-year increase of 14.5%. Segment data reveals the core 'Smokeable Products' segment generated $5.12 billion, while the 'Smokeless Products' segment contributed $706 million, indicating the business remains heavily reliant on traditional tobacco despite growth in alternatives. The revenue trend shows variability, with the prior quarter (Q3 2025) at $5.25 billion, suggesting some quarterly volatility in top-line performance. The company is highly profitable, posting net income of $1.12 billion in Q4 2025 and an impressive trailing net margin of 34.5%. Gross margin for the quarter was 62.1%, though the trailing twelve-month gross margin is a robust 86.6%, highlighting the inherent profitability of the tobacco business. Profitability has been consistent, with net income positive in every recent quarter, though margins can fluctuate due to one-time items and tax impacts, as seen in the net margin compression from 59.5% in Q4 2024 to 19.1% in Q4 2025. The balance sheet shows significant financial leverage, with a debt-to-equity ratio of -7.34, a negative figure stemming from negative shareholder equity, which is a notable risk factor. However, cash generation is strong, with trailing free cash flow of $9.07 billion, providing ample coverage for the substantial dividend payout (payout ratio of 100.2%) and share repurchases. The current ratio of 0.61 indicates relatively low liquidity, which is typical for the industry but warrants monitoring given the high debt load.
Quarterly Revenue
$5.8B
2025-12
Revenue YoY Growth
+0.14%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MO Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. Altria trades at a trailing PE of 13.9x and a forward PE of 12.0x. The lower forward multiple suggests the market anticipates modest earnings growth. The forward PE of 12.0x is based on an estimated EPS of $6.39, implying a forward-looking valuation discount to the trailing figure. Compared to sector averages, the stock's valuation presents a mixed picture. Its trailing PE of 13.9x is below the typical market average for profitable companies, reflecting the perceived risks associated with the tobacco industry's long-term decline and regulatory pressures. The Price-to-Sales ratio of 4.8x and EV/EBITDA of 10.9x provide additional context, but the PE remains the most relevant for this profitable entity. Historically, the stock's own valuation has been volatile. The current trailing PE of 13.9x sits below the higher end of its recent historical range observed in the provided data (e.g., 21.6x in Q4 2025, 7.3x in Q4 2024). This positioning suggests the stock is not at historical valuation extremes, potentially offering a reasonable entry point if the fundamental dividend story holds, but it also reflects the market's cautious stance on future growth.
PE
13.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -8x~81x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, primarily centered on Altria's leveraged balance sheet. The debt-to-equity ratio of -7.34, resulting from negative shareholder equity, is a severe red flag, indicating the company's assets are significantly outweighed by liabilities. While strong free cash flow of $9.07B covers the dividend, the 100.2% payout ratio leaves minimal room for error. Furthermore, earnings volatility is high, with net margin swinging from 59.5% to 19.1% year-over-year, and the business remains overwhelmingly dependent on combustible tobacco, which generated 88% of last quarter's revenue.
Market & Competitive Risks stem from the stock's defensive nature and industry headwinds. While the low beta of 0.519 offers downside protection, it also implies chronic underperformance in strong bull markets, as seen in its -8.0% relative strength over the past year. The company faces relentless regulatory pressure, potential new taxes, and continuous volume decline in its core market. Its valuation, though reasonable at a 12.0x forward P/E, could compress further if the transition to smoke-free products falters or if investor sentiment shifts decisively away from 'sin stocks'.
Worst-Case Scenario involves a perfect storm where cigarette volume decline accelerates faster than pricing power can offset, leading to a sustained drop in cash flow. This could force a dividend cut, triggering a mass exodus of income investors. Simultaneously, failed investments in reduced-risk products like Njoy and Cronos would eliminate the growth narrative. In this adverse scenario, the stock could realistically re-test its 52-week low of $54.70, representing a downside of approximately -23% from the current price of $70.60. The historical max drawdown of -19.15% provides a recent benchmark for potential losses during periods of stress.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Extreme balance sheet leverage with a debt-to-equity ratio of -7.34, which could strain the company during an economic downturn. 2) Secular Risk: The long-term, irreversible decline in cigarette smoking, which threatens the core cash-generating business. 3) Dividend Sustainability Risk: The payout ratio of 100.2% leaves no room for a significant drop in free cash flow, which is currently $9.07B. 4) Execution Risk: The company's investments in reduced-risk products (Njoy, Cronos) may fail to achieve meaningful scale to offset the core decline.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $65 and $74.56, as it maintains its dividend and navigates steady volume decline. The Bull Case (25% probability) targets $74.56 to $80.00, driven by successful growth in smoke-free products. The Bear Case (15% probability) could see a re-test of support between $54.70 and $60.00 if dividend concerns escalate. The Base Case is most likely, predicated on the assumption that the company's pricing power and cash flow remain stable in the near term.
MO appears fairly valued relative to its risk profile. The primary metric, the forward P/E of 12.0x, is below the trailing P/E of 13.9x and reflects modest earnings growth expectations. Compared to the broader market, this is a discount, but it is appropriate given the industry's headwinds. The valuation implies the market expects the company to manage a gradual decline while maintaining its dividend, not to deliver significant growth. It is not cheap enough to be deeply undervalued nor expensive enough to be considered overvalued, given its cash-generative nature.
MO is a good buy only for a specific type of investor: those seeking high current income who are fully aware of and comfortable with the long-term secular risks. The 7.2% dividend yield is compelling, and the forward P/E of 12.0x is not excessive. However, the severe debt-to-equity ratio of -7.34 and the company's dependence on a declining cigarette business make it unsuitable for growth-oriented or risk-averse investors. It is a tactical hold for income portfolios rather than a core growth holding.
MO is primarily suitable for long-term, income-oriented investment with a minimum holding period of 3-5 years. Its low beta of 0.519 makes it a poor candidate for short-term trading, as it typically exhibits lower volatility and tends to underperform in strong bull markets. The investment thesis is based on collecting the high dividend yield over time, not on capital appreciation. Given the secular challenges, a long-term horizon allows the investor to realize the cumulative income while monitoring the company's strategic transition, though the very long-term (10+ years) outlook remains highly uncertain.